代表性论著、科研获奖、人才称号 |
一、代表性论著： 1.IL-36A axis suppression associates with clinical response to stapokibart in head and neck atopic dermatitis—an exploratory proteomic study.Journal of the American Academy of Dermatology.Accepted.末位通讯作者(皮肤领域顶刊，IF=11.8，Q1) 2.Oral Dapsone in Refractory Rosacea: A Prospective Exploratory Study Defining a “High Inflammatory Burden” Subtype and a Testable Precision Treatment Hypothesis.Journal of the American Academy of Dermatology. Accepted.末位通讯作者(皮肤领域顶刊，IF=11.8，Q1) 3.Xu, B., Qing, Y., Wang, Y., Xu, Z., Ye, S., Zhao, B., Sun, H., Wu, N., & Wu, J. (2025). Efficacy and safety of oral JAK1 inhibitor upadacitinib monotherapy for papulopustular rosacea: A real-world study.Journal of the American Academy of Dermatology, 93(2), 540–542.唯一通讯作者(皮肤领域顶刊，IF=11.8，Q1) 4.Xu, B., Wu, J., Xu, Z., Qing, Y., Wang, Y., Ye, S., Yu, B., Zhao, B., Sun, H., Wu, N., & Yang, Y. (2025). Optimized combination: Isotretinoin in conjunction with oral tranexamic acid for the treatment of moderate to severe acne vulgaris-A randomized, double-blind, placebo-controlled trial.Journal of the American Academy of Dermatology, 93(5), 1312–1314.共同第一作者、唯一通讯作者(皮肤领域顶刊，IF=11.8，Q1) 5.Xu, B., & Wu, J. (2026). Response to He et al's "Comments on 'Optimized combination: Isotretinoin in conjunction with oral tranexamic acid for the treatment of moderate to severe acne vulgaris-A randomized, double-blind, placebo-controlled trial'".Journal of the American Academy of Dermatology, S0190-9622(26)00251-3. Advance online publication.唯一通讯作者(皮肤领域顶刊，IF=11.8，Q1) 6.Xu, B., Xiao, S., & Wu, J. (2025). Response to Zhang et al, "Isotretinoin combined with oral tranexamic acid for moderate-to-severe acne vulgaris: Evidence gaps and future directions".Journal of the American Academy of Dermatology, S0190-9622(25)03261-X. Advance online publication.末位通讯作者(皮肤领域顶刊，IF=11.8，Q1) 7.Wu, J., Wang, Y., Qing, Y., Xu, B., Yang, Y., Sun, H., & Wu, N. (2025). Burden of acne vulgaris, psoriasis, atopic dermatitis, and urticaria in individuals under 20 years of age in China and globally, 1990-2021: A systematic analysis with 10-year forecast.JAAD international, 24, 323–325.共同第一作者、唯一通讯作者(IF=5.2，Q1) 8.Qing, Y., Wu, J., Xu, B., Xu, Z., Ye, S., Wang, Y., Zhao, B., Sun, H., & Wu, N. (2025). DNAJB2 Attenuates Rosacea Skin Inflammation and Angiogenesis by Inhibiting the Endoplasmic Reticulum Stress-mediated TLR2/Myd88/NF-κB pathway.Inflammation, 48(5), 3472–3486.共同第一作者、唯一通讯作者(IF=5，Q1) 9.Xu, Z., Yu, B., Qing, Y., Ye, S., Xu, B., Wang, Y., Zhao, B., Sun, H., Wu, N., & Wu, J. (2025). Efficacy and Safety of Topical Compound Heparin Sodium Allantoin Gel (Main Components: Onion Extract Quercetin) for the Treatment of Rosacea.Journal of cosmetic dermatology, 24(4), e70129.唯一通讯作者(IF=2.5，Q2 ) 10.Xu, Z., Yu, B., Xu, B., Ye, S., Qing, Y., Zhao, B., Hong, S., Wu, N., & Wu, J. (2025). Response to Comments on "Oral Tranexamic Acid Treats Papulopustular Rosacea by Improving the Skin Barrier".Journal of cosmetic dermatology, 24(4), e70151.唯一通讯作者(IF=2.5，Q2) 11.Xu, B., Yu, B., Xu, Z., Ye, S., Qing, Y., Sun, H., Zhao, B., Wu, N., & Wu, J. (2024). Investigation and Confirmation of PYCARD as a Potential Biomarker for the Management of Psoriasis Disease.Journal of inflammation research, 17, 6415–6437.唯一通讯作者(IF=4.2，Q2) 12.Xu, Z., Xu, B., Zhao, B., Gao, H., Ye, S., & Wu, J. (2024). Treatment of refractory psoriasis with dermatomyositis using upadacitinib.Clinical and experimental rheumatology, 42(2), 458–459.唯一通讯作者(IF=3.3，Q2) 13.Ye, S., Yu, B., Wu, J., Xu, Z., Xu, B., Sun, H., & Zhao, B. (2024). Effect of the JAK1 Inhibitor, Upadacitinib, on Skin Barrier Repair of Eczema Elicited During Anti-Interleukin-17 Treatment for Psoriasis.Dermatitis : contact, atopic, occupational, drug, 35(5), 537–539.唯一通讯作者(IF=5.2，Q1) 14.Xu, Z., Yu, B., Xu, B., Ye, S., Qing, Y., Zhao, B., Hong, S., Wu, N., & Wu, J. (2024). Oral tranexamic acid treats papulopustular rosacea by improving the skin barrier.Journal of cosmetic dermatology, 23(9), 2918–2926.唯一通讯作者(IF=2.5，Q2) 15.Xu, B., Xu, Z., Ye, S., Sun, H., Zhao, B., Wu, N., & Wu, J. (2023). JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea: case series.Frontiers in medicine, 10, 1239869.唯一通讯作者(IF=3.9，Q2) 16.Ye, S., Sun, H., Xu, Z., Xu, B., Wu, N., & Wu, J. (2023). A study of the efficacy and safety of plaque psoriasis treatment by TNF-α and IL-17A inhibitor biologics in patients who received the inactivated SARS-CoV-2 vaccine.Immunity, inflammation and disease, 11(7), e938.唯一通讯作者(IF=3.2，Q3) 二、科研获奖： 1.口服JAK1抑制剂乌帕替尼单药治疗丘疹脓疱型玫瑰痤疮的疗效和安全性：一项真实世界研究，第二十届中国医师协会皮肤科医师年会暨全国美容皮肤科学大会，优秀论文奖； 2.2025年Wiley威立中国高贡献作者奖, Wiley出版社 3.2024年Wiley威立中国高贡献作者奖, Wiley出版社 4.第五届全国皮肤屏障高峰会“优秀临床研究”奖,上海交通大学医学院附属瑞金医院联合玉泽医学护肤研究基金会 |
